218 related articles for article (PubMed ID: 32728528)
1. Immunotherapy - new perspective in lung cancer.
Pinheiro FD; Teixeira AF; de Brito BB; da Silva FAF; Santos MLC; de Melo FF
World J Clin Oncol; 2020 May; 11(5):250-259. PubMed ID: 32728528
[TBL] [Abstract][Full Text] [Related]
2. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
3. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
4. A Network Meta-Analysis of Cancer Immunotherapies
Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
Front Oncol; 2021; 11():676732. PubMed ID: 34307144
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
7. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
[TBL] [Abstract][Full Text] [Related]
8. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
10. First line Immunotherapy for Non-Small Cell Lung Cancer.
Nasser NJ; Gorenberg M; Agbarya A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171686
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
12. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Scarpace SL
Drugs Context; 2015; 4():212289. PubMed ID: 26576187
[TBL] [Abstract][Full Text] [Related]
13. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy in the Treatment of Lung Cancer].
Fiala O; Šorejs O; Pešek M; Fínek J
Klin Onkol; 2017; 30(Supplementum3):22-31. PubMed ID: 29239189
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
16. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Cetin B; Bilgetekin İ; Ozet A
Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
[TBL] [Abstract][Full Text] [Related]
17. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
West HJ; Kim JY
JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
[TBL] [Abstract][Full Text] [Related]
18. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
19. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
20. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Low JL; Walsh RJ; Ang Y; Chan G; Soo RA
Ther Adv Med Oncol; 2019; 11():1758835919870360. PubMed ID: 31497071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
